Biology of Blood and Marrow Transplantation
Volume 14, Issue 5 , Pages 485-498 , May 2008

The Clinical Outcome of Hurler Syndrome after Stem Cell Transplantation

  • Mieke Aldenhoven

      Affiliations

    • Department of Immunology/Hematology and Stem Cell Transplantations, University Medical Center Utrecht, Utrecht, The Netherlands
    • Corresponding Author InformationCorrespondence and written requests: Mieke Aldenhoven, Department of Immunology/Metabolic Diseases, Room KC 03.063.0, University Medical Center Utrecht, Lundlaan 6, 3584 EA, Utrecht, The Netherlands, Phone: +31(0)887554003; Fax: +31(0)887555350.
    • ,
  • JaapJan Boelens

      Affiliations

    • Department of Immunology/Hematology and Stem Cell Transplantations, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Tom J. de Koning

      Affiliations

    • Department of Metabolic Diseases; University Medical Center Utrecht, Utrecht, The Netherlands

References 

  1. Hobbs JR, Hugh-Jones K, Barrett AJ, et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 1981;2:709–712
  2. Neufeld EF, Muenzer J. The Mucopolysaccharidosis. In:  Scriver C,  Beaudet A,  Sly W,  Valle D editor. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill; 2001;p. 3421–3452
  3. Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother. 2005;6:489–506
  4. Roubicek M, Gehler J, Spranger J. The clinical spectrum of alpha-L-iduronidase deficiency. Am J Med Genet. 1985;20:471–481
  5. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28:1011–1017
  6. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101:355–358
  7. Jeyakumar M, Dwek RA, Butters TD, et al. Storage solutions: treating lysosomal disorders of the brain. Nat Rev Neurosci. 2005;6:713–725
  8. Vellodi A. Lysosomal storage disorders. Br J Haematol. 2005;128:413–431
  9. Walkley SU. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol. 2004;15:433–444
  10. Constantopoulos G, Dekaban AS. Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls. J Neurochem. 1978;30:965–973
  11. Constantopoulos G, Iqbal K, Dekaban AS. Mucopolysaccharidosis types IH, IS, II, and IIIA: glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues. J Neurochem. 1980;34:1399–1411
  12. Chamoles NA, Blanco MB, Gaggioli D, et al. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem. 2001;47:2098–2102
  13. Cleary MA, Wraith JE. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr. 1995;84:337–339
  14. Colville GA, Bax MA. Early presentation in the mucopolysaccharide disorders. Child Care Health Dev. 1996;22:31–36
  15. Pastores GM, Arn P, Beck M, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab. 2007;91:37–47
  16. Fratantoni JC, Hall CW, Neufeld EF. The defect in Hurler and Hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation. Proc Natl Acad Sci U.S.A. 1969;64:360–366
  17. Di Ferrante N, Nichols BL, Donnelly PV, et al. Induced degradation of glycosaminoglycans in Hurler's and Hunter's syndromes by plasma infusion. Proc Natl Acad Sci U.S.A. 1971;68:303–307
  18. Krivit W, Sung JH, Shapiro EG, et al. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 1995;4:385–392
  19. EBMT registry. http://www.ebmt.org/4Registry/registry1.html. 2007. Ref Type: Electronic Citation.
  20. IBMTR registry. http://www.cibmtr.org. 2007. Ref Type: Electronic Citation.
  21. Souillet G, Guffon N, Maire I, et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003;31:1105–1117
  22. Vellodi A, Young EP, Cooper A, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child. 1997;76:92–99
  23. Peters C, Shapiro EG, Anderson J, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood. 1998;91:2601–2608
  24. Church H, Tylee K, Cooper A, et al. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant. 2007;39:207–210
  25. Guffon N, Souillet G, Maire I, et al. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr. 1998;133:119–125
  26. Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet. 1993;46:209–218
  27. Hopwood JJ, Vellodi A, Scott HS, et al. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J Inherit Metab Dis. 1993;16:1024–1033
  28. Leighton SE, Papsin B, Vellodi A, et al. Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2001;58:127–138
  29. Semenza GL, Pyeritz RE. Respiratory complications of mucopolysaccharide storage disorders. Medicine (Baltimore). 1988;67:209–219
  30. Myer CM. Airway obstruction in Hurler's syndrome–radiographic features. Int J Pediatr Otorhinolaryngol. 1991;22:91–96
  31. Shapiro J, Strome M, Crocker AC. Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol. 1985;94:458–461
  32. Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995;345:1398–1402
  33. Fleming DR, Henslee-Downey PJ, Ciocci G, et al. The use of partially HLA-mismatched donors for allogeneic transplantation in patients with mucopolysaccharidosis-I. Pediatr Transplant. 1998;2:299–304
  34. Malone BN, Whitley CB, Duvall AJ, et al. Resolution of obstructive sleep apnea in Hurler syndrome after bone marrow transplantation. Int J Pediatr Otorhinolaryngol. 1988;15:23–31
  35. Belani KG, Krivit W, Carpenter BL, et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. J Pediatr Surg. 1993;28:403–408
  36. Vinallonga X, Sanz N, Balaguer A, et al. Hypertrophic cardiomyopathy in mucopolysaccharidoses: regression after bone marrow transplantation. Pediatr Cardiol. 1992;13:107–109
  37. Gatzoulis MA, Vellodi A, Redington AN. Cardiac involvement in mucopolysaccharidoses: effects of allogeneic bone marrow transplantation. Arch Dis Child. 1995;73:259–260
  38. Braunlin EA, Stauffer NR, Peters CH, et al. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2003;92:882–886
  39. Braunlin EA, Rose AG, Hopwood JJ, et al. Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2001;88:1075–1077
  40. Brosius FC, Roberts WC. Coronary artery disease in the Hurler syndrome. Qualitative and quantitative analysis of the extent of coronary narrowing at necropsy in six children. Am J Cardiol. 1981;47:649–653
  41. Braunlin EA, Hunter DW, Krivit W, et al. Evaluation of coronary artery disease in the Hurler syndrome by angiography. Am J Cardiol. 1992;69:1487–1489
  42. Stauffer N, Braunlin E, Whitley C, et al. Echocardiographic follow-up of Hurler syndrome after bone marrow transplantation. Circulation. 1991;84(suppl II):462a
  43. Braunlin EA, Krivit W, Burke BA, et al. Radiological case of the month. Coarctation of the aorta in Hurler syndrome. Arch Pediatr Adolesc Med. 2000;154:841–842
  44. Connock M, Juarez-Garcia A, Frew E, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess. 2006;10:1-113
  45. Shull RM, Hastings NE, Selcer RR, et al. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system. J Clin Invest. 1987;79:435–443
  46. Shull RM, Breider MA, Constantopoulos GC. Long-term neurological effects of bone marrow transplantation in a canine lysosomal storage disease. Pediatr Res. 1988;24:347–352
  47. Ellinwood NM, Colle MA, Weil MA, et al. Bone marrow transplantation for feline mucopolysaccharidosis I. Mol Genet Metab. 2007;91:239–250
  48. Breider MA, Shull RM, Constantopoulos G. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. Am J Pathol. 1989;134:677–692
  49. Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis. 1995;18:413–429
  50. Peters C, Balthazor M, Shapiro EG, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood. 1996;87:4894–4902
  51. Staba SL, Escolar ML, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med. 2004;350:1960–1969
  52. Krivit W, Sung J, Lockman L, et al. Bone marrow transplantation for treatment of lysosomal and peroxisomal storage diseases: Focus on central nervous system reconstitution. In:  Rich R,  Fleisher T,  Schwarts B,  Shearer W,  Strober W editor. Principles of Clinical Immunology. St. Louis: Mosby; 1995;p. 1852–1864
  53. Sugar J. Corneal manifestations of the systemic mucopolysaccharidoses. Ann Ophthalmol. 1979;11:531–535
  54. Summers CG, Purple RL, Krivit W, et al. Ocular changes in the mucopolysaccharidoses after bone marrow transplantation. A preliminary report. Ophthalmology. 1989;96:977–984
  55. Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology. 1998;105:1099–1105
  56. Fahnehjelm KT, Tornquist AL, Malm G, Winiarski J. Ocular findings in four children with mucopolysaccharidosis I-Hurler (MPS I-H) treated early with haematopoietic stem cell transplantation. Acta Ophthalmol Scand. 2006;84:781–785
  57. Tzetzi D, Hamilton R, Robinson PH, Dutton GN. Negative ERGs in mucopolysaccharidoses (MPS) Hurler-Scheie (I-H/S) and Hurler (I-H)-syndromes. Doc Ophthalmol. 2007;114:153–158
  58. Collins ML, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology. 1990;97:1445–1449
  59. Komura Y, Kaga K, Ogawa Y, et al. ABR and temporal bone pathology in Hurler's disease. Int J Pediatr Otorhinolaryngol. 1998;43:179–188
  60. Krivit W, Lockman LA, Watkins PA, et al. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis. 1995;18:398–412
  61. Bredenkamp JK, Smith ME, Dudley JP, et al. Otolaryngologic manifestations of the mucopolysaccharidoses. Ann Otol Rhinol Laryngol. 1992;101:472–478
  62. Field RE, Buchanan JA, Copplemans MG, et al. Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development. J Bone Joint Surg Br. 1994;76:975–981
  63. Wraith JE, Alani SM. Carpal tunnel syndrome in the mucopolysaccharidoses and related disorders. Arch Dis Child. 1990;65:962–963
  64. Haddad FS, Jones DH, Vellodi A, et al. Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses. J Bone Joint Surg Br. 1997;79:576–582
  65. Hite SH, Peters C, Krivit W. Correction of odontoid dysplasia following bone-marrow transplantation and engraftment (in Hurler syndrome MPS 1H). Pediatr Radiol. 2000;30:464–470
  66. Tandon V, Williamson JB, Cowie RA, et al. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br. 1996;78:938–944
  67. Weisstein JS, Delgado E, Steinbach LS, et al. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop. 2004;24:97–101
  68. Odunusi E, Peters C, Krivit W, et al. Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: correction by surgical intervention. J Pediatr Orthop. 1999;19:270–274
  69. Masterson EL, Murphy PG, O'meara A, et al. Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J Pediatr Orthop. 1996;16:731–733
  70. Van Heest AE, House J, Krivit W, et al. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg.[Am.]. 1998;23:236–243
  71. Khanna G, Van Heest AE, Agel J, et al. Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant. 2007;39:331–334
  72. Kachur E, Del MR. Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. Neurosurgery. 2000;47:223–228
  73. Fisher RC, Horner RL, Wood VE. The hand in mucopolysaccharide disorders. Clin Orthop Relat Res. 1974;191–199
  74. Bjoraker KJ, Delaney K, Peters C, Krivit W, Shapiro EG. Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation. J Dev Behav Pediatr. 2006;27:290–296
  75. Wraith JE. Limitations of enzyme replacement therapy: current and future. J Inherit Metab Dis. 2006;29:442–447
  76. Pastores GM, Meere PA. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol. 2005;17:70–78
  77. Chung S, Ma X, Liu Y, et al. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab. 2007;90:181–192
  78. Hendriksz CJ, Moss GM, Wraith JE. Pregnancy in a patient with mucopolysaccharidosis type IH homozygous for the W402X mutation. J Inherit Metab Dis. 2004;27:685–686
  79. Krivit W, Henslee-Downey J, Klemperer M, et al. Survival in Hurler's disease following bone marrow transplantation in 84 patients. Bone Marrow Transplant. 1995;15:S182–S185
  80. Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol. 1999;12:167–176
  81. Scott HS, Ashton LJ, Eyre HJ, et al. Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3. Am J Hum Genet. 1990;47:802–807
  82. The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. http://www.hgmd.cf.ac.uk/ac/gene.php?gene=IDUA. 2007. Ref Type: Electronic Citation.
  83. Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med. 2003;5:286–294
  84. Bunge S, Kleijer WJ, Steglich C, et al. Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common alpha-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet. 1994;3:861–866
  85. Gort L, Chabas A, Coll MJ. Analysis of five mutations in 20 mucopolysaccharidois type 1 patients: high prevalence of the W402X mutation. Mutations in brief no. 121. Online. Hum Mutat. 1998;11:332–333
  86. Beesley CE, Meaney CA, Greenland G, et al. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet. 2001;109:503–511
  87. Boelens JJ, Wynn RF, O'meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40:225–233
  88. Conway J, Dyack S, Crooks BN, et al. Mixed donor chimerism and low level iduronidase expression may be adequate for neurodevelopmental protection in Hurler Syndrome. J Pediatr. 2005;147:106–108
  89. Boelens J, Bierings M, Wynn R, et al. Outcomes of Cord Blood Transplantation for Hurler's syndrome. An EUROCORD-Working Party Inborn Errors EBMT Survey. [abstract] Biol Blood Marrow Transplant. 2007;13(suppl I):59
  90. Martin PL, Carter SL, Kernan NA, et al. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant. 2006;12:184–194
  91. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005;352:2069–2081
  92. Stein J, Zion GB, Dror Y, et al. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur J Pediatr. 2007;166:663–666
  93. Chao NJ, Emerson SG, Weinberg KI. Stem cell transplantation (cord blood transplants). Hematology. Am Soc Hematol Educ Program. 2004:354–371.
  94. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335:157–166
  95. Boelens JJ. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis. 2006;29:413–420
  96. Kogler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004;200:123–135
  97. Chen N, Hudson JE, Walczak P, et al. Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural. Stem Cells. 2005;23:1560–1570
  98. Meier C, Middelanis J, Wasielewski B, et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res. 2006;59:244–249
  99. Peters C, Shapiro EG, Krivit W. Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation. Pediatr Transplant. 1998;2:250–253
  100. Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood. 1997;90:986–993
  101. European group for Bone and Marrow Transplantation (EBMT)-guidelines. www.EBMT.org. 2007. Ref Type: Electronic Citation.
  102. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344:182–188
  103. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144:581–588
  104. Brooks DA. Alpha-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Biol Ther. 2002;2:967–976
  105. Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120:e37–e46
  106. Tokic V, Barisic I, Huzjak N, et al. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur J Pediatr. 2007;166:727–732
  107. Thomas JA, Jacobs S, Kierstein J, et al. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome. J Inherit Metab Dis. 2006;29:762
  108. Tolar J, Grewal SS, Bjoraker KJ, et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant. 2007;
  109. Cox-Brinkman J, Boelens JJ, Wraith JE, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant. 2006;38:17–21
  110. Grewal SS, Wynn R, Abdenur JE, et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7:143–146
  111. Koc ON, Peters C, Aubourg P, et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol. 1999;27:1675–1681
  112. Koc ON, Day J, Nieder M, et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 2002;30:215–222
  113. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet. 2007;121:1–22
  114. Ellinwood NM, Vite CH, Haskins ME. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med. 2004;6:481–506
  115. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA. 2003;290:2564–2572
  116. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254
  117. Meikle PJ, Brooks DA, Ravenscroft EM, et al. Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Clin Chem. 1997;43:1325–1335
  118. Li Y, Scott CR, Chamoles NA, et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem. 2004;50:1785–1796
  119. Wilson, JMG and Jungner, G. Principles and practice of screening for disease. Geneva: World Health Organization. Public Health Paper No 34. 1968. Ref Type: Report.

PII: S1083-8791(08)00052-9

doi: 10.1016/j.bbmt.2008.01.009

Biology of Blood and Marrow Transplantation
Volume 14, Issue 5 , Pages 485-498 , May 2008

Article Tools

* Image Usage & Resolution